FDA approves Janssen’s AKEEGA to treat prostate cancer
The approval is based on the positive results from the Phase III MAGNITUDE study.
14 August 2023
14 August 2023
The approval is based on the positive results from the Phase III MAGNITUDE study.
Clinigen announced that the four drugs will join CNX Therapeutics’ pharmaceutical portfolio.
ZetaMAST is a percutaneous, intra-tumoural injection that will be developed to treat metastatic lesions to soft tissue organs.
The off-the-shelf ProtoNK cell products treat cancer, viral infections and autoimmune conditions.
TriSalus is breaking into immuno-oncology area with its TLR agonist SD-101 for treating solid tumours.
The latest tag adds to three fast track designations for Reqorsa, with the company initiating a Phase I/II trial in Q4 2023.
The payment is part of Oxurion’s subscription agreement with Atlas totalling up to $25m.
The organisation’s Padeliporfin VTP therapy platform will be used to develop eye disease treatment.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Give your business an edge with our leading industry insights.